BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26038957)

  • 1. Nivolumab in renal cell carcinoma.
    Michel Ortega RM; Drabkin HA
    Expert Opin Biol Ther; 2015 Jul; 15(7):1049-60. PubMed ID: 26038957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab for the treatment of cancer.
    Gunturi A; McDermott DF
    Expert Opin Investig Drugs; 2015 Feb; 24(2):253-60. PubMed ID: 25494679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
    Farolfi A; Schepisi G; Conteduca V; Burgio SL; Lolli C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1089-96. PubMed ID: 27450183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab: targeting PD-1 to bolster antitumor immunity.
    Brahmer JR; Hammers H; Lipson EJ
    Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in the treatment of advanced renal cell carcinoma.
    Arasaratnam M; Gurney H
    Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint inhibition: new treatment options in urologic cancer.
    De Maeseneer DJ; Delafontaine B; Rottey S
    Acta Clin Belg; 2017 Feb; 72(1):24-28. PubMed ID: 28151378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab for treating non-small cell lung cancer.
    Guibert N; Mazières J
    Expert Opin Biol Ther; 2015; 15(12):1789-97. PubMed ID: 26574148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study.
    Bedke J; Grimm MO; Grünwald V
    Future Oncol; 2018 May; 14(11):1023-1034. PubMed ID: 29325434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
    Harshman LC; Drake CG; Choueiri TK
    Cancer Immunol Res; 2014 Dec; 2(12):1132-41. PubMed ID: 25480555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma.
    Gao X; McDermott DF
    Expert Opin Biol Ther; 2018 Sep; 18(9):947-957. PubMed ID: 30124333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.